Kyntra Bio, Inc. (KYNB)
NASDAQ: KYNB · Real-Time Price · USD
5.28
+0.43 (8.87%)
At close: Oct 19, 2026, 4:00 PM EDT
5.28
0.00 (0.00%)
After-hours: Oct 19, 2026, 4:00 PM EDT
Kyntra Bio Employees
Kyntra Bio had 34 employees as of December 31, 2025. The number of employees decreased by 191 or -84.89% compared to the previous year. That makes Kyntra Bio the 36,639th largest employer in the world and 5,052nd in the United States.
Employees
34
Change (1Y)
-191
Growth (1Y)
-84.89%
Revenue / Employee
$135,765
Profits / Employee
$5,388,000
Market Cap
21.38M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 34 | -191 | -84.89% |
| Dec 31, 2024 | 225 | -261 | -53.70% |
| Dec 31, 2023 | 486 | -106 | -17.91% |
| Dec 31, 2022 | 592 | 26 | 4.59% |
| Dec 31, 2021 | 566 | -33 | -5.51% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fractyl Health | 100 |
| aTyr Pharma | 60 |
| Quantum BioPharma | 17 |
| Context Therapeutics | 15 |
| Cocrystal Pharma | 10 |
| Quoin Pharmaceuticals | 6 |
| Akari Therapeutics, | 6 |
| Marker Therapeutics | 5 |
KYNB News
- 6 days ago - Kyntra Bio initiated with a Buy at Maxim on mCRPC potential - TheFly
- 6 days ago - Kyntra Bio initiated with a Buy at Maxim - TheFly
- 18 days ago - Kyntra Bio appoints Singer to its board of directors - TheFly
- 18 days ago - Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors - GlobeNewsWire
- 4 weeks ago - Kyntra Bio initiated with a Buy at Lake Street on prostate cancer potential - TheFly
- 4 weeks ago - Kyntra Bio initiated with a Buy at Lake Street - TheFly
- 4 weeks ago - Kyntra Bio Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 6 weeks ago - Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire